(Q37984208)

26 August 2017

title

Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights (English)

1 reference

chronic renal insufficiency

26 August 2017

1 reference

1 reference

7

Wolfgang Jelkmann

1 reference

26 August 2017

12

Carol Pollock

1 reference

26 August 2017

Iain C Macdougall

1

1 reference

26 August 2017

Simon D Roger

2

1 reference

26 August 2017

Angel de Francisco

3

1 reference

26 August 2017

David J A Goldsmith

4

1 reference

26 August 2017

Huub Schellekens

5

1 reference

26 August 2017

Hans Ebbers

6

1 reference

26 August 2017

Gérard London

8

1 reference

26 August 2017

Nicole Casadevall

9

1 reference

26 August 2017

Walter H Hörl

10

1 reference

26 August 2017

David M Kemeny

11

1 reference

26 August 2017

language of work or name

English

0 references

publication date

15 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

81

1 reference

26 August 2017

issue

8

1 reference

26 August 2017

page(s)

727-732

1 reference

Epoetin-associated pure red cell aplasia: past, present, and future considerations

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Pure red cell aplasia induced by erythropoiesis-stimulating agents.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

On the Role of Aggregates in the Immunogenicity of Recombinant Human Interferon Beta in Patients with Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Erythropoietin-Associated PRCA: Still an Unsolved Mystery

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Autoantibodies against erythropoietin in a patient with pure red-cell aplasia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Immunological mechanism underlying the immune response to recombinant human protein therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Quality of original and biosimilar epoetin products

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Impact of illegal trade on the quality of epoetin alfa in Thailand.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Pure red cell aplasia due to follow-on epoetin.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Biosimilars-why terminology matters

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Tungsten-induced protein aggregation: solution behavior

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Precipitation of a monoclonal antibody by soluble tungsten

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Human immune response to recombinant human proteins

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Pure red-cell aplasia and epoetin therapy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Immunogenicity of biopharmaceuticals

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Recovery from anti-recombinant-human-erythropoietin associated pure red cell aplasia in end-stage renal disease patients after renal transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1*09-DQB1*0309.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.500

7 January 2021

Identifiers

DOI

10.1038/KI.2011.500

1 reference

26 August 2017

1 reference